- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- Adults
Research at a glance
Top areas of exploration
- alpha 1-Antitrypsin Deficiency , 11 publications
- Pulmonary Disease, Chronic Obstructive , 9 publications
- alpha 1-Antitrypsin , 8 publications
- Lung , 4 publications
Research activity
Active clinical trials
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- Both
- Sexes
- All
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- Adults
- Sexes
- All
My publications
Filter publications
48 publications
2026
Polymerized Z-α-1 antitrypsin leads to lung injury in a murine model of emphysema.
JCI insight
PubMed • Publisher's site2026
Epidemiology of Alpha-1 Antitrypsin Deficiency in the Veterans Health Administration.
Annals of the American Thoracic Society
PubMed • Publisher's site2026
Cardiovascular disease-associated admissions in patients with Cystic Fibrosis: A 7-Year U.S. National Inpatient Sample Analysis.
Heart & lung : the journal of critical care
PubMed • Publisher's site2025
High BMI and COPD Outcomes in Alpha-1 Antitrypsin Deficiency.
CHEST pulmonary
PubMed • Publisher's site2025
Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.
ERJ open research
PubMed • Publisher's site